Protagonist Therapeutics, Inc financial data

Symbol
PTGX on Nasdaq
Location
7707 Gateway Blvd., Suite 140, Newark, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.46K % +6.25%
Debt-to-equity 8.54 % -28.5%
Return On Equity 6.86 % -80.2%
Return On Assets 6.32 % -79.6%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 62.5M shares +4.9%
Common Stock, Shares, Outstanding 62.4M shares +4.91%
Entity Public Float 2B USD +25%
Common Stock, Value, Issued 1K USD 0%
Weighted Average Number of Shares Outstanding, Basic 63.8M shares +3.25%
Weighted Average Number of Shares Outstanding, Diluted 63.8M shares +3.25%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 148M USD +11.9%
General and Administrative Expense 42.4M USD -0.44%
Operating Income (Loss) 19M USD -87.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 48.1M USD -72.2%
Income Tax Expense (Benefit) 2.16M USD -3.05%
Net Income (Loss) Attributable to Parent 45.9M USD -73.1%
Earnings Per Share, Basic 0 USD/shares -74.6%
Earnings Per Share, Diluted 0 USD/shares -76.4%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 114M USD -13.3%
Marketable Securities, Current 462M USD +37%
Other Assets, Current 191K USD -92.8%
Assets, Current 586M USD +23%
Property, Plant and Equipment, Net 4.1M USD +66.1%
Operating Lease, Right-of-Use Asset 8.17M USD -16.9%
Assets 702M USD +16.2%
Accounts Payable, Current 5.65M USD +85.2%
Accrued Liabilities, Current 22.9M USD +10.3%
Liabilities, Current 44.9M USD +0.82%
Operating Lease, Liability, Noncurrent 8.52M USD -21.5%
Liabilities 56.3M USD -21.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax 525K USD -60.7%
Retained Earnings (Accumulated Deficit) -426M USD +9.72%
Stockholders' Equity Attributable to Parent 645M USD +21.3%
Liabilities and Equity 702M USD +16.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 125M USD
Net Cash Provided by (Used in) Financing Activities 11.4M USD +59%
Net Cash Provided by (Used in) Investing Activities -94.4M USD -1655%
Common Stock, Shares Authorized 180M shares 0%
Common Stock, Shares, Issued 62.4M shares +4.91%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 42.4M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 114M USD -13.2%
Deferred Tax Assets, Valuation Allowance 115M USD -30.6%
Deferred Tax Assets, Gross 118M USD -29.4%
Operating Lease, Liability 10.9M USD +852%
Payments to Acquire Property, Plant, and Equipment 545K USD +125%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 45.1M USD -73.8%
Lessee, Operating Lease, Liability, to be Paid 12.6M USD +989%
Property, Plant and Equipment, Gross 12M USD +28.1%
Operating Lease, Liability, Current 2.23M USD +4851%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.79M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.16M USD -0.09%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure -48.1%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.77M USD +9211%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.88M USD
Deferred Tax Assets, Operating Loss Carryforwards 8.88M USD -87.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 30.6M USD +9.09%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.98M USD
Operating Lease, Payments 696K USD +3.26%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 239K USD +1.27%
Share-based Payment Arrangement, Expense 44.4M USD +26.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%